Mikhail Kolmogorov

Investigator

National Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Cancer is fundamentally a disease of the genome, characterized by extensive genomic, transcriptomic, and epigenomic alterations. Most current studies predominantly use short-read sequencing, gene panels, or microarrays to explore these alterations; however, these technologies can systematically miss or misrepresent certain types of alterations, especially structural variants, complex rearrangements, and alterations within repetitive regions. Long-read sequencing is rapidly emerging as a transformative technology for cancer research by providing a comprehensive view across the genome, transcriptome, and epigenome, including the ability to detect alterations that previous technologies have overlooked. In this Perspective, we explore the current applications of long-read sequencing for both germline and somatic cancer analysis. We provide an overview of the computational methodologies tailored to long-read data and highlight key discoveries and resources within cancer genomics that were previously inaccessible with prior technologies. We also address future opportunities and persistent challenges, including the experimental and computational requirements needed to scale to larger sample sizes, the hurdles in sequencing and analyzing complex cancer genomes, and opportunities for leveraging machine learning and artificial intelligence technologies for cancer informatics. We further discuss how the telomere-to-telomere genome and the emerging human pangenome could enhance the resolution of cancer genome analysis, potentially revolutionizing early detection and disease monitoring in patients. Finally, we outline strategies for transitioning long-read sequencing from research applications to routine clinical practice.

Year:

2025

The Genome in a Bottle Consortium (GIAB), hosted by the National Institute of Standards and Technology (NIST), is developing new matched tumor-normal samples, the first explicitly consented for public dissemination of genomic data and cell lines. Here, we describe a comprehensive genomic dataset from the first individual, HG008, including DNA from an adherent, epithelial-like pancreatic ductal adenocarcinoma (PDAC) tumor cell line and matched normal cells from duodenal and pancreatic tissues. Data for the tumor-normal matched samples comes from seventeen distinct state-of-the-art whole genome measurement technologies, including high depth short and long-read bulk whole genome sequencing (WGS), single cell WGS, Hi-C, and karyotyping. These data will be used by the GIAB Consortium to develop matched tumor-normal benchmarks for somatic variant detection. We expect these data to facilitate innovation for whole genome measurement technologies, de novo assembly of tumor and normal genomes, and bioinformatic tools to identify small and structural somatic variants. This first-of-its-kind broadly consented open-access resource will facilitate further understanding of sequencing methods used for cancer biology.

Year:

2025

Year:

2025

The chromosome 5p15.33 region, which encodes telomerase reverse transcriptase (TERT), harbors multiple germline variants identified by genome-wide association studies (GWAS) as risk for some cancers but protective for others. Here, we characterize a variable number tandem repeat within TERT intron 6, VNTR6-1 (38-bp repeat unit), and detect a strong link between VNTR6-1 alleles (Short: 24-27 repeats, Long: 40.5-66.5 repeats) and GWAS signals rs2242652 and rs10069690 within TERT intron 4. Bioinformatics analyses reveal that rs10069690-T allele increases intron 4 retention while VNTR6-1-Long allele expands a polymorphic G-quadruplex (G4, 35-113 copies) within intron 6, with both variants contributing to variable TERT expression through alternative splicing and nonsense-mediated decay. In two cell lines, CRISPR/Cas9 deletion of VNTR6-1 increases the ratio of TERT- full-length (FL) to the alternative TERT-β isoform, promoting apoptosis and reducing cell proliferation. In contrast, treatment with G4-stabilizing ligands shifts splicing from TERT-FL to TERT-β isoform, implicating VNTR6-1 as a splicing switch. We associate the functional variants VNTR6-1, rs10069690, and their haplotypes with multi-cancer risk and age-related telomere shortening. By regulating TERT splicing, these variants may contribute to fine-tuning cellular longevity and replicative potential in the context of stress due to tissue-specific endogenous and exogenous exposures, thereby influencing the cancer risk conferred by this locus.

Year:

2025

Objective Variants in PRKN and PINK1 are the leading cause of early‐onset autosomal recessive Parkinson's disease, yet many cases remain genetically unresolved. We previously identified a 7 megabases complex structural variant in a pair of monozygotic twins using Oxford Nanopore Technologies (ONT) long‐read sequencing. This study aims to determine if ONT long‐read sequencing can detect a second variant in other unresolved early‐onset Parkinson's disease (EOPD) cases with 1 heterozygous PRKN or PINK1 variant. Methods ONT long‐read sequencing was performed on EOPD patients with 1 reported PRKN / PINK1 pathogenic variant, with onset age under 50. Positive controls included EOPD patients with 2 known PRKN pathogenic variants. Initial testing involved short‐read targeted panel sequencing for single nucleotide variants and multiplex ligation‐dependent probe amplification for copy number variants. Results A total of 47 patients were studied ( PRKN “one‐variant,” n = 23; PINK1 “one‐variant,” n = 12; PRKN “two‐variants,” n = 12). ONT long‐read sequencing identified a second pathogenic variant in 26% of PRKN “one‐variant” patients (6/23), but none in PINK1 “one‐variant” patients (0/12). Detected variants included 1 complex inversion, 2 structural variant overlaps, and 3 duplications. In the PRKN “two‐variants” group, both variants were identified in all patients (100%, 12/12). Interpretation ONT long‐read sequencing effectively identifies pathogenic structural variants in the PRKN locus missed by conventional methods. It should be considered for unresolved EOPD cases when a second variant is not detected through conventional approaches. ANN NEUROL 2025;97:753–765

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (36)

Mihai Pop

Professor

University of Maryland at College Park

UNITED STATES
View details

Shloka Negi

University of California, Santa Cruz

UNITED STATES
View details

Michael Schatz

Bloomberg Distinguished Professor

Johns Hopkins University

UNITED STATES
View details

Andrea Guarracino

Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details

Sonja Scholz

National Institute of Neurological Disorders and Stroke

UNITED STATES
View details

Claudia Gonzaga-Jauregui

Associate Professor (with Tenure)

National Autonomous University of Mexico

View details

PHILLIP RICHMOND

Research Associate Professor

University of Colorado Boulder

UNITED STATES
View details

Fritz Sedlazeck

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Karen H. Miga

Associate Professor

University of California, Santa Cruz

UNITED STATES
View details

Heer Mehta

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Xylena Reed

Staff Scientist

National Institute on Aging

UNITED STATES
View details

Erik Garrison

Associate Professor

University of Tennessee Health Science Center

UNITED STATES
View details

Gabrielle Lemire

Lecturer

University of Ottawa

CANADA
View details

Justin Zook

National Institute of Standards and Technology

UNITED STATES
View details

Mitchell Machiela

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Winston Timp

Joint Appointment

Johns Hopkins University

UNITED STATES
View details

Jean Monlong

Permanent Researcher CRCN

INSERM

FRANCE
View details

Oscar Flórez-Vargas

Staff Scientist

National Cancer Institute

UNITED STATES
View details

Alison Klein

Professor

-

UNITED STATES
View details

Seth Berger

Associate Professor

Children's National Health System

UNITED STATES
View details

Evan Eichler

Howard Hughes Medical Institute

UNITED STATES
View details

Danny Miller

Assistant Professor

University of Washington

UNITED STATES
View details

Stephen Montgomery

Associate Professor

Stanford University

UNITED STATES
View details

Hua-Jun He

National Institute of Standards and Technology

UNITED STATES
View details

Xian Chang

University of California, Santa Cruz

UNITED STATES
View details

Matthew Loose

Professor

University of Nottingham

UNITED KINGDOM
View details

Eric Vilain

University of California

UNITED STATES
View details

Nathanael Olson

National Institute of Standards and Technology

UNITED STATES
View details

Yue Hao

Research Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details

Shahinaz Gadalla

National Institutes of Health

UNITED STATES
View details

Salem Malikic

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Jennifer McDaniel

National Institute of Standards and Technology

UNITED STATES
View details

Harriet Dashnow

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Zhiyong He

National Institute of Standards and Technology

UNITED STATES
View details

W. Richard McCombie

Professor

Cold Spring Harbor Laboratory

UNITED STATES
View details

Anne O'Donnell-Luria

Associate Professor

Boston Children's Hospital

UNITED STATES
View details